News|Articles|June 1, 2026

Real-World Evidence in Clinical Trials: Where the Industry Stands and Where It's Headed

As the FDA formally recognizes real-world evidence as eligible confirmatory evidence for drug approval, sponsors face a growing imperative to build the data infrastructure, organizational alignment, and analytical capabilities needed to use RWE effectively across the development lifecycle.

Real-world evidence (RWE) has been moving steadily upstream in drug development. With the FDA now explicitly recognizing RWE as eligible confirmatory evidence under its updated single-trial standard, the question is no longer whether RWE belongs in clinical development, but how to build the infrastructure and organizational capabilities to use it effectively.

Related to this article

The Next Evolution of Patient-Centered Trials Starts with Design
Decentralized trial success depends less on how far activities move away from sites than on matching each activity’s delivery model to participant burden, site readiness, and data integrity, using patient intelligence to decide where flexibility helps and where site-based care remains essential.
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.